BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. [PMID: 11156649 DOI: 10.1136/gut.48.2.251] [Cited by in Crossref: 455] [Cited by in F6Publishing: 408] [Article Influence: 21.7] [Reference Citation Analysis]
Number Citing Articles
1 Izumi N, Asahina Y, Tsuchiya K, Kurosaki M, Nakanishi H, Kitamura T, Uchihara M, Miyake S. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatology Research 2007;37:S254-63. [DOI: 10.1111/j.1872-034x.2007.00193.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Wolf D. Screening for hepatocellular carcinoma: Is it cost-effective? Liver Transplantation 2003;9:682-3. [DOI: 10.1053/jlts.2003.50139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
3 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
4 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
5 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas. World J Surg. 2006;30:1567-1578. [PMID: 16855807 DOI: 10.1007/s00268-005-0249-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
8 Pompili M, Riccardi L, Covino M, Barbaro B, Di Stasi C, Orefice R, Gasbarrini G, Rapaccini GL. Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int. 2005;25:954-961. [PMID: 16162152 DOI: 10.1111/j.1478-3231.2005.01135.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
9 Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235-251, vi. [PMID: 15831271 DOI: 10.1016/j.cld.2004.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
10 Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679-690. [PMID: 12650806 DOI: 10.1111/j.1572-0241.2003.07327.x] [Cited by in Crossref: 188] [Cited by in F6Publishing: 153] [Article Influence: 9.9] [Reference Citation Analysis]
11 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
13 Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc. 2010;109:39-55. [PMID: 20123585 DOI: 10.1016/s0929-6646(10)60020-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
14 Wang XW, Thorgeirsson SS. Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol 2009;50:1062-4. [PMID: 19328580 DOI: 10.1016/j.jhep.2009.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
15 Jia KD, Zou ZY, Lv DY. The Value of Survivin Gene and Proliferation of Hepatocytes in Screening for Hepatocellular Carcinoma. Gastroenterology Res 2009;2:333-7. [PMID: 27990202 DOI: 10.4021/gr2009.12.1326] [Reference Citation Analysis]
16 Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci 2008;5:327-32. [PMID: 18974861 DOI: 10.7150/ijms.5.327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
17 Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol 2012;6:441-4. [PMID: 22928896 DOI: 10.1586/egh.12.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, Little AF. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61:34-39. [PMID: 27558976 DOI: 10.1111/1754-9485.12513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
19 Okamoto E, Sato S, Sanchez-Siles AA, Ishine J, Miyake T, Amano Y, Kinoshita Y. Evaluation of virtual CT sonography for enhanced detection of small hepatic nodules: a prospective pilot study. AJR Am J Roentgenol 2010;194:1272-8. [PMID: 20410414 DOI: 10.2214/AJR.08.2294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Jin BX, Zhang YH, Jin WJ, Sun XY, Qiao GF, Wei YY, Sun LB, Zhang WH, Li N. MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep. 2015;5:15026. [PMID: 26456479 DOI: 10.1038/srep15026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
21 Seror O, N′kontchou G, Haddar D, Dordea M, Ajavon Y, Ganne N, Trinchet JC, Beaugrand M, Sellier N. Large Infiltrative Hepatocellular Carcinomas: Treatment with Percutaneous Intraarterial Ethanol Injection Alone or in Combination with Conventional Percutaneous Ethanol Injection. Radiology 2005;234:299-309. [DOI: 10.1148/radiol.2341031008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
22 Maida M, Malizia G, Affronti A, Virdone R, Maida C, Margherita V, D’amico G. Screening and surveillance for hepatocellular carcinoma: perspective of a new era? Expert Review of Anticancer Therapy 2016;16:1291-302. [DOI: 10.1080/14737140.2016.1246965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 753] [Article Influence: 40.1] [Reference Citation Analysis]
24 Wang X, Wang Y, Zhang Q, Zhuang H, Chen B. MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and Is an Unfavorable Prognostic Biomarker. Med Sci Monit 2018;24:1759-67. [PMID: 29576605 DOI: 10.12659/msm.909012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1384] [Article Influence: 83.2] [Reference Citation Analysis]
26 Nguyen VT, Amin J, Law MG, Dore GJ. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol. 2009;24:436-442. [PMID: 19175834 DOI: 10.1111/j.1440-1746.2008.05577.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
27 Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920-925. [PMID: 24224722 DOI: 10.1111/jgh.12439] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
28 Yamashiki N, Yoshida H, Tateishi R, Shiina S, Teratani T, Yoshida H, Kondo Y, Oki T, Kawabe T, Omata M. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J Gastroenterol Hepatol 2007;22:2155-60. [DOI: 10.1111/j.1440-1746.2006.04732.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
29 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer 2012;1:257-66. [PMID: 24159590 DOI: 10.1159/000343840] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
32 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
33 Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007;13:857-66. [DOI: 10.1002/lt.21155] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
34 Heo JY, Kim BK, Park JY, Kim DY, Ahn SH, Kim HS, Park YN, Han KH, Song K, Kim SU. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut Liver 2018;12:190-200. [PMID: 29069887 DOI: 10.5009/gnl17092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
36 Grewal P, Martin P. Care of the cirrhotic patient. Clin Liver Dis 2009;13:331-40. [PMID: 19442922 DOI: 10.1016/j.cld.2009.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
37 Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J. [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp 2008;84:117-24. [PMID: 18783669 DOI: 10.1016/s0009-739x(08)72152-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
38 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.4] [Reference Citation Analysis]
39 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
40 Inagaki Y, Xu HL, Hasegawa K, Aoki T, Beck Y, Sugawara Y, Tang W, Kokudo N. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J Dig Dis. 2011;12:481-488. [PMID: 22118699 DOI: 10.1111/j.1751-2980.2011.00521.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
41 Chu YD, Lin WR, Lin YH, Kuo WH, Tseng CJ, Lim SN, Huang YL, Huang SC, Wu TJ, Lin KH, Yeh CT. COX5B-Mediated Bioenergetic Alteration Regulates Tumor Growth and Migration by Modulating AMPK-UHMK1-ERK Cascade in Hepatoma. Cancers (Basel) 2020;12:E1646. [PMID: 32580279 DOI: 10.3390/cancers12061646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204-1212. [PMID: 15122748 DOI: 10.1002/hep.20169] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
43 Jakovljevic M, Trahey GE, Nelson RC, Dahl JJ. In vivo application of short-lag spatial coherence imaging in human liver. Ultrasound Med Biol 2013;39:534-42. [PMID: 23347642 DOI: 10.1016/j.ultrasmedbio.2012.09.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
44 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102-107. [PMID: 15213625 DOI: 10.1097/01.sla.0000129672.51886.44] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 9.9] [Reference Citation Analysis]
45 Lee JH, Tak WY, Lee Y, Heo MK, Song JS, Kim HY, Park SY, Bae SH, Lee JH, Heo J, Kim KH, Bae YS, Kim YJ. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology 2017;6:e1328335. [PMID: 28811965 DOI: 10.1080/2162402X.2017.1328335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
46 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
47 Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189-CR195. [PMID: 21455104 DOI: 10.12659/msm.881714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
48 Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P. Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. Gastroenterol Res Pract. 2014;2014:529314. [PMID: 25165471 DOI: 10.1155/2014/529314] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
49 da Rocha MC, Marinho RT, Rodrigues T. Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012. GE Port J Gastroenterol 2018;25:123-31. [PMID: 29761148 DOI: 10.1159/000484868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
50 Jakab Z. [Diagnostic imaging for the screening of hepatocellular carcinoma]. Orv Hetil 2010;151:1083-90. [PMID: 20558357 DOI: 10.1556/OH.2010.28912] [Reference Citation Analysis]
51 Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169-71. [PMID: 12354833 DOI: 10.1016/s1051-0443(07)61783-7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
52 Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS One 2016;11:e0166157. [PMID: 27829060 DOI: 10.1371/journal.pone.0166157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
53 Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, Fraquelli M, Riccardi L, De Bonis L, Sangiovanni A, Leoni S, Zocco MA, Rossi S, Alessi N, Wilson SR, Piscaglia F;  CEUS LI-RADS Italy study group collaborators:. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol. 2018;68:485-492. [PMID: 29133247 DOI: 10.1016/j.jhep.2017.11.007] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 17.6] [Reference Citation Analysis]
54 Shindo K, Maekawa S, Komatsu N, Tatsumi A, Miura M, Sato M, Suzuki Y, Matsuda S, Muraoka M, Amemiya F, Fukasawa M, Yamaguchi T, Nakayama Y, Uetake T, Inoue T, Sakamoto M, Sato T, Enomoto N. Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma. Mediators Inflamm 2015;2015:687484. [PMID: 26494948 DOI: 10.1155/2015/687484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
55 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal of Hepatology 2008;48:848-57. [DOI: 10.1016/j.jhep.2008.02.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
56 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
58 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172. [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
59 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
60 Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108-S112. [PMID: 15508073 DOI: 10.1053/j.gastro.2004.09.023] [Cited by in Crossref: 233] [Cited by in F6Publishing: 209] [Article Influence: 12.9] [Reference Citation Analysis]
61 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
62 Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S, Merkesdal S, Galanski M, Manns MP, Bleck JS. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006; 12(23): 3707-3715 [PMID: 16773687 DOI: 10.3748/wjg.v12.i23.3707] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
63 Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J. 2008;14:100-110. [PMID: 18391615 DOI: 10.1097/ppo.0b013e31816a5c1f] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
64 Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005;42:27-34. [PMID: 15954118 DOI: 10.1002/hep.20728] [Cited by in Crossref: 308] [Cited by in F6Publishing: 270] [Article Influence: 18.1] [Reference Citation Analysis]
65 Wong LL, Tsai N, Limm W, Wong L. Liver transplant for hepatocellular cancer: a treatment for the select few. Clin Transplant 2004;18:205-10. [PMID: 15016137 DOI: 10.1046/j.1399-0012.2003.00157.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
66 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
67 Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005;11:1117-1126. [PMID: 16123960 DOI: 10.1002/lt.20469] [Cited by in Crossref: 136] [Cited by in F6Publishing: 128] [Article Influence: 8.0] [Reference Citation Analysis]
68 Lencioni R. Surveillance and early diagnosis of hepatocellular carcinoma. Digestive and Liver Disease 2010;42:S223-7. [DOI: 10.1016/s1590-8658(10)60509-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
69 Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-1179. [PMID: 17635075 DOI: 10.1515/cclm.2007.262] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
70 Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, Fargion S. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35:498-503. [PMID: 11682034 DOI: 10.1016/s0168-8278(01)00160-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
71 Lin TL, Yap AQ, Wang JH, Chen CL, Iyer SG, Low JK, Lin CC, Li WF, Chen TY, Bora D, Lin CY, Wang CC. Long term survival in patients with hepatocellular carcinoma directly invading the gastrointestinal tract: case reports and literature review. Surg Oncol 2011;20:e207-14. [PMID: 21824763 DOI: 10.1016/j.suronc.2011.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Xu XL, Liu XD, Liang M, Luo BM. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology 2018;287:461-72. [PMID: 29135366 DOI: 10.1148/radiol.2017162756] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 21.0] [Reference Citation Analysis]
73 Huang MA, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2002;18:345-50. [DOI: 10.1097/00001574-200205000-00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1710-1719 [PMID: 18350602 DOI: 10.3748/wjg.14.1710] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
75 Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, Bae YS, Kim YJ. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76. [PMID: 26657650 DOI: 10.1038/bjc.2015.430] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 6.1] [Reference Citation Analysis]
76 Neumaier CE, Cittadini G, Grasso A, Dahmane M. Role of ultrasonography in the staging of gastrointestinal neoplasms. Semin Surg Oncol 2001;20:86-90. [DOI: 10.1002/ssu.1022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
77 Kong D, Chen H, Chen W, Liu S, Wang H, Wu T, Lu H, Kong Q, Huang X, Lu Z. Gene expression profiling analysis of hepatocellular carcinoma. Eur J Med Res 2013;18:44. [PMID: 24229431 DOI: 10.1186/2047-783X-18-44] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Masuzaki R, Yoshida H, Kato N, Omata M. Hepatitis C and Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Carcinoma. Totowa: Humana Press; 2010. pp. 259-81. [DOI: 10.1007/978-1-60327-376-3_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S86-S91. [PMID: 12394211 DOI: 10.1097/00004836-200211002-00004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
80 Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, Hori M, Nagano H, Wakasa K, Hayashi N, Murakami T. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-13. [PMID: 20490505 DOI: 10.1007/s00330-010-1812-9] [Cited by in Crossref: 176] [Cited by in F6Publishing: 158] [Article Influence: 14.7] [Reference Citation Analysis]
81 Ando E, Kuromatsu R, Tanaka M, Takada A, Fukushima N, Sumie S, Nagaoka S, Akiyoshi J, Inoue K, Torimura T, Kumashiro R, Ueno T, Sata M. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol 2006;40:942-8. [PMID: 17063116 DOI: 10.1097/01.mcg.0000225675.14594.d6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
82 Bruix J. HCC surveillance: Who is the target population? Hepatology 2003;37:507-9. [DOI: 10.1053/jhep.2003.50142] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
83 Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885-894. [PMID: 21319193 DOI: 10.1002/hep.24121] [Cited by in Crossref: 256] [Cited by in F6Publishing: 240] [Article Influence: 23.3] [Reference Citation Analysis]
84 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
85 Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009; 15(26): 3217-3227 [PMID: 19598296 DOI: 10.3748/wjg.15.3217] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
86 Chen S, Xu XL, Zhou B, Tian J, Luo BM, Zhang LM. Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. ACS Appl Mater Interfaces 2019;11:22194-205. [PMID: 31199110 DOI: 10.1021/acsami.9b06745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
87 Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver Imaging Reporting and Data System: Review of Pros and Cons. Semin Liver Dis 2021. [PMID: 34298576 DOI: 10.1055/s-0041-1732356] [Reference Citation Analysis]
88 Lencioni R, Della Pina C, Cioni D, Crocetti L. Guidelines for the use of contrast-enhanced ultrasound in hepatocellular carcinoma. European Journal of Cancer Supplements 2008;6:1-8. [DOI: 10.1016/j.ejcsup.2008.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
90 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
91 Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin SD, Liu R. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 2014;14:83. [PMID: 25360068 DOI: 10.1186/s12935-014-0083-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
92 Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, Gamboa-Domínguez A, Arrieta O. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. Clin Oncol (R Coll Radiol) 2007;19:197-203. [PMID: 17359907 DOI: 10.1016/j.clon.2006.12.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
93 Zhong J, Ma L, Li L. Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2014;49:649-61. [DOI: 10.3109/00365521.2014.905626] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
94 Chui A, Wong J, Rao A, Ng S, Chan F, Chan H, Chan C, Mi R, Lau W. High incidence of incidental hepatocellular carcinoma exists among hepatitic explanted livers. Transplantation Proceedings 2003;35:350-1. [DOI: 10.1016/s0041-1345(02)04010-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Cho HJ, Kim B, Lee JD, Kang DR, Kim JK, Lee JH, Shin SJ, Lee KM, Yoo BM, Lee KJ. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. Am J Gastroenterol. 2017;112:460-470. [PMID: 27779194 DOI: 10.1038/ajg.2016.480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
96 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
97 Reddy SI, Grace ND. Liver imaging. A hepatologist's perspective. Clin Liver Dis 2002;6:297-310, ix. [PMID: 11933595 DOI: 10.1016/s1089-3261(03)00077-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
98 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 339] [Article Influence: 45.5] [Reference Citation Analysis]
99 Maluf D, Fisher RA, Maroney T, Cotterell A, Fulcher A, Tisnado J, Contos M, Luketic V, Stravitz R, Shiffman M. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003;3:312-317. [PMID: 12614287 DOI: 10.1034/j.1600-6143.2003.00041.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
100 Theodoropoulos J, Brooks A. Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. The American Surgeon 2011;77:207-14. [DOI: 10.1177/000313481107700223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Yu C, Wu S, Zhao J, Lu J, Zhao T, Wei Y, Long C, Lin T, He D, Wei G. Evaluation of efficacy, safety and treatment-related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the Milan criteria: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2020;44:718-32. [PMID: 31959566 DOI: 10.1016/j.clinre.2019.12.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Wang BM, Li N. Effect of the Wnt/β-catenin signaling pathway on apoptosis, migration, and invasion of transplanted hepatocellular carcinoma cells after transcatheter arterial chemoembolization in rats. J Cell Biochem 2018;119:4050-60. [PMID: 29232009 DOI: 10.1002/jcb.26576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
103 Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215-219. [PMID: 15050913 DOI: 10.1016/s1535-6108(04)00058-3] [Cited by in Crossref: 414] [Cited by in F6Publishing: 190] [Article Influence: 23.0] [Reference Citation Analysis]
104 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 196] [Article Influence: 28.9] [Reference Citation Analysis]
105 Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, Fisher RA. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007;39:153-9. [PMID: 17275495 DOI: 10.1016/j.transproceed.2006.10.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
106 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
107 Bolondi L. Screening tests for hepatocellular carcinoma. Hepatology 2003;37:1493; author reply 1493. [PMID: 12774028 DOI: 10.1053/jhep.2003.50215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
109 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
110 Azab M, Zaki S, El-Shetey AG, Abdel-Moty MF, Alnoomani NM, Gomaa AA, Abdel-Fatah S, Mohiy S, Atia F. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab J Gastroenterol. 2011;12:113-118. [PMID: 22055587 DOI: 10.1016/j.ajg.2011.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
111 Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl 2018;24:1171-7. [PMID: 29781162 DOI: 10.1002/lt.25202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
112 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 571] [Article Influence: 41.1] [Reference Citation Analysis]
113 Shriki JE, Seyal AR, Dighe MK, Yeh MM, Jalikis FG, Andeen NK, Lall C, Bhargava P. CT of Atypical and Uncommon Presentations of Hepatocellular Carcinoma. AJR Am J Roentgenol 2015;205:W411-23. [PMID: 26397348 DOI: 10.2214/AJR.14.14000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
114 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
115 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Mendizabal M, Reddy KR. Current Management of Hepatocellular Carcinoma. Medical Clinics of North America 2009;93:885-900. [DOI: 10.1016/j.mcna.2009.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
117 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
118 De Simone P, Carrai P, Baldoni L, Petruccelli S, Coletti L, Morelli L, Filipponi F. Quality assurance, efficiency indicators and cost-utility of the evaluation workup for liver transplantation. Liver Transpl 2005;11:1080-5. [DOI: 10.1002/lt.20484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
119 Wai-sun Wong V, Lik-yuen Chan H. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology 2012;11:284-93. [DOI: 10.1016/s1665-2681(19)30922-6] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
120 Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577. [PMID: 20978844 DOI: 10.1007/s10620-010-1453-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
121 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
122 Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, Pulitano C, Majno P, Mira P, Rubbia-brandt L, Ferrero A, Aldrighetti L, Cunningham S, Russolillo N, Philosophe B, Barroso E, Pawlik TM. Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation? J Gastrointest Surg 2008;12:1699-708. [DOI: 10.1007/s11605-008-0652-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
123 Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18. [PMID: 18184025 DOI: 10.2165/00002512-200825010-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
124 Kim DY, Han KH. Impact of a shortened surveillance interval on hepatocellular carcinoma survival. Hepat Oncol 2014;1:3-5. [PMID: 30190934 DOI: 10.2217/hep.13.1] [Reference Citation Analysis]
125 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1064] [Article Influence: 155.6] [Reference Citation Analysis]
126 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
127 Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles HC, Maluf DG, Cotterell AH, Posner MP, Fisher RA. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119-126. [PMID: 18261500 DOI: 10.1016/j.amjmed.2007.09.020] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 7.4] [Reference Citation Analysis]
128 Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, Spradling PR, Adhikari BB, McMahon BJ. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. Int J Circumpolar Health 2016;75:31115. [PMID: 27197711 DOI: 10.3402/ijch.v75.31115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
129 Molmenti EP, Klein AS. Liver transplantation for hepatocellular carcinoma: . Current Opinion in Organ Transplantation 2002;7:124-8. [DOI: 10.1097/00075200-200206000-00003] [Reference Citation Analysis]
130 Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao J, Li LQ. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012;7:e32159. [PMID: 22403631 DOI: 10.1371/journal.pone.0032159] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
131 Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127:S248-S260. [PMID: 15508091 DOI: 10.1053/j.gastro.2004.09.039] [Cited by in Crossref: 152] [Cited by in F6Publishing: 152] [Article Influence: 8.4] [Reference Citation Analysis]
132 Kuo MJ, Chen HH, Chen CL, Fann JCY, Chen SLS, Chiu SYH, Lin YM, Liao CS, Chang HC, Lin YS, Yen AMF. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol 2016; 22(12): 3460-3470 [PMID: 27022228 DOI: 10.3748/wjg.v22.i12.3460] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
133 Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758-1767. [PMID: 17087938 DOI: 10.1053/j.gastro.2006.09.014] [Cited by in Crossref: 287] [Cited by in F6Publishing: 247] [Article Influence: 17.9] [Reference Citation Analysis]
134 Qiao G, Li J, Huang A, Yan Z, Lau WY, Shen F. Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:2014-2020. [PMID: 24989634 DOI: 10.1111/jgh.12672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
135 Park MS, Han K, Kim SU. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology 2014;8:501-11. [DOI: 10.1586/17474124.2014.898563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
136 Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9:e98612. [PMID: 24874413 DOI: 10.1371/journal.pone.0098612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
137 Ding YT. Research progress of liver resection for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(10): 955-961 [DOI: 10.11569/wcjd.v17.i10.955] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
138 Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005;42:358-64. [PMID: 15710218 DOI: 10.1016/j.jhep.2004.11.020] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
139 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
140 Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27:638-643. [PMID: 25831135 DOI: 10.1097/meg.0000000000000341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
141 Shen XF, Zeng XT, Jian ZY, Zhou M, Zhou P, Zhang M. Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma. Oncol Lett 2015;10:3199-205. [PMID: 26722312 DOI: 10.3892/ol.2015.3723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
143 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
144 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
145 Grazi GL. Liver resections: complications and survival outcome. Expert Rev Pharmacoecon Outcomes Res 2007;7:269-79. [PMID: 20528313 DOI: 10.1586/14737167.7.3.269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
147 Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ, Orloff SL. A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. Am J Surg 2012;203:182-90. [PMID: 21679921 DOI: 10.1016/j.amjsurg.2011.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
148 Masuzaki R, Omata M. HCC Screening and Surveillance. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 26-35. [DOI: 10.3109/9780203092880-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004;99:1470-1476. [PMID: 15307862 DOI: 10.1111/j.1572-0241.2004.30137.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 5.0] [Reference Citation Analysis]
150 Zhou S, Tan C, Dai Z, Zhu H, Xu M, Zhou Z, Wang W, Zhao Y, Fu X, Zhou J, Fan J. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. Transplant Proc 2011;43:2747-54. [PMID: 21911157 DOI: 10.1016/j.transproceed.2011.06.040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
151 Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013; 19(40): 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
152 Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011-1017. [PMID: 17936698 DOI: 10.1016/j.dld.2007.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
153 Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297. [PMID: 20483497 DOI: 10.1016/j.jhep.2010.03.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 15.3] [Reference Citation Analysis]
154 Yeo YH, Hwang J, Jeong D, Dang N, Kam LY, Henry L, Park H, Cheung R, Nguyen MH. Surveillance of patients with cirrhosis remains suboptimal in the United States. J Hepatol 2021:S0168-8278(21)00307-X. [PMID: 33965477 DOI: 10.1016/j.jhep.2021.04.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
156 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
157 Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, Eguchi Y, Anzai K. Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival. Intern Med. 2016;55:2749-2758. [PMID: 27725532 DOI: 10.2169/internalmedicine.55.6730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
158 Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:607-33, ix. [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
159 Bolondi L. State of the art: hepatocellular carcinoma. Future Oncology 2014;10:1-6. [DOI: 10.2217/fon.14.215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
160 Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnée M, Montigny P, D'alincourt A, Hamy A, Paineau J, Le Néel J-, Le Borgne J, Galmiche JP. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis: PERCUTANEOUS ETHANOL INJECTION VS. RESECTION IN HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2002;16:1529-38. [DOI: 10.1046/j.1365-2036.2002.01307.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
161 Pompili M, Riccardi L, Semeraro S, Orefice R, Elia F, Barbaro B, Covino M, Grieco A, Gasbarrini G, Rapaccini GL. Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. Dig Liver Dis. 2008;40:206-215. [PMID: 18054850 DOI: 10.1016/j.dld.2007.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
162 Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol. 2013;27:961-972. [PMID: 24182614 DOI: 10.1016/j.bpg.2013.08.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
163 Wang J, Lu S, Hung C, Chen T, Chen C, Changchien C, Lee C. Small hepatic nodules (?2�cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int 2006;26:928-34. [DOI: 10.1111/j.1478-3231.2006.01318.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
164 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
165 Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, Tong L, Berg CL; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-62. [PMID: 19177435 DOI: 10.1002/lt.21671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
166 Cho SJ, Kim YJ, Surh YJ, Kim BM, Lee SK. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem 2011;286:19662-71. [PMID: 21478145 DOI: 10.1074/jbc.M110.209551] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
167 Huang GQ, Xie YY, Zhu PW, Wang XD, Lin Z, Wang Y, Ye JP, Wang YM, Chen YX, Jin XZ, Van Poucke S, Chen YP, Zheng MH. Stratified alpha-fetoprotein pattern accurately predicts mortality in patients with acute-on-chronic hepatitis B liver failure. Expert Rev Gastroenterol Hepatol 2018;12:295-302. [PMID: 29300103 DOI: 10.1080/17474124.2018.1424540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
168 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
169 Caturelli E, Ghittoni G, Roselli P, De Palo M, Anti M. Fine needle biopsy of focal liver lesions: The hepatologist's point of view. Liver Transpl 2004;10:S26-9. [DOI: 10.1002/lt.20037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
170 Hung CS, Liu HH, Liu JJ, Yeh CT, Chang TC, Wu CH, Ho YS, Wei PL, Chang YJ. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol. 2013;20 Suppl 3:S360-S368. [PMID: 22868917 DOI: 10.1245/s10434-012-2482-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
171 El Moety AAA, El Moety HA. Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma. Alexandria Journal of Medicine 2011;47:31-5. [DOI: 10.1016/j.ajme.2011.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
172 Kennedy NA, Rodgers A, Altus R, McCormick R, Wundke R, Wigg AJ. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J 2013;43:772-7. [PMID: 23611607 DOI: 10.1111/imj.12166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
173 Berliner L, Lemke HU, vanSonnenberg E, Ashamalla H, Mattes MD, Dosik D, Hazin H, Shah S, Mohanty S, Verma S, Esposito G, Bargellini I, Battaglia V, Caramella D, Bartolozzi C, Morrison P. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J 2014;5:16. [PMID: 25538797 DOI: 10.1186/1878-5085-5-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
174 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
175 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
176 Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837, viii. [PMID: 17981230 DOI: 10.1016/j.cld.2007.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
177 Kim DY, Kim HJ, Jeong SE, Kim SG, Kim HJ, Sinn DH, Lee YJ, Jeong WK, Choi KS, Heo N, Kim DJ, Kim YS, Kim YB, Kim YJ, Kim H, Park M, Lee CW, Tak WY, Chung JH, Kim SY, Kim Y, Lee W, Kim HS. The Korean guideline for hepatocellular carcinoma surveillance. J Korean Med Assoc 2015;58:385. [DOI: 10.5124/jkma.2015.58.5.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
178 Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M; Italian Liver Cancer Group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol 2007;102:2448-57; quiz 2458. [PMID: 17617210 DOI: 10.1111/j.1572-0241.2007.01395.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
179 Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416-423. [PMID: 12640447 DOI: 10.1038/nm843] [Cited by in Crossref: 591] [Cited by in F6Publishing: 538] [Article Influence: 31.1] [Reference Citation Analysis]
180 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 386] [Article Influence: 34.9] [Reference Citation Analysis]
181 Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
182 Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265-273. [PMID: 16858190 DOI: 10.1097/01.sla.0000217921.28563.55] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 6.1] [Reference Citation Analysis]
183 Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;:101799. [PMID: 34500120 DOI: 10.1016/j.clinre.2021.101799] [Reference Citation Analysis]
184 Nicolau C, Bianchi L, Vilana R. Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention. Semin Ultrasound CT MR. 2002;23:3-18. [PMID: 11866221 DOI: 10.1016/s0887-2171(02)90026-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
185 Prieto M, Aguilera V, Berenguer M, Pina R, Benlloch S. Selección de candidatos para trasplante hepático. Gastroenterología y Hepatología 2007;30:42-53. [DOI: 10.1157/13097451] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
186 Lake-Bakaar G, Ahmed M, Evenson A, Bonder A, Faintuch S, Sundaram V. Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer 2014;3:428-38. [PMID: 26280004 DOI: 10.1159/000343871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
187 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
188 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
189 Mohanty S, Verma S, Dosik D, Hazin H, Berliner L. Hepatocellular Carcinoma and Patient Assessment. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 21-32. [DOI: 10.1007/978-3-319-12166-6_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 D'Onofrio M, Faccioli N, Zamboni G, Malagò R, Caffarri S, Fattovich G, Mucelli RP. Focal liver lesions in cirrhosis: value of contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels. Radiol Med 2008;113:978-91. [PMID: 18779929 DOI: 10.1007/s11547-008-0316-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
191 Li J, Liu Y, Yan Z, Wan X, Xia Y, Wang K, Liu J, Lau WY, Wu M, Shen F. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer 2014;110:1110-7. [PMID: 24481404 DOI: 10.1038/bjc.2014.19] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
192 Qiao G, Cucchetti A, Li J, Cescon M, Ercolani G, Liu G, Pinna AD, Li L, Shen F, Ren J. Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. Oncotarget 2016;7:30408-19. [PMID: 27007152 DOI: 10.18632/oncotarget.8149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
193 Wu C, Hsu Y, Ho HJ, Chen Y, Lee T, Lin J. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut 2016;65:693-701. [DOI: 10.1136/gutjnl-2014-308786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
194 Seror O, N'Kontchou G, Tin Tin Htar M, Durand-Zaleski I, Trinchet JC, Sellier N, Beaugrand M. Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. Gastroenterol Clin Biol. 2006;30:1265-1273. [PMID: 17185968 DOI: 10.1016/S0399-8320(06)73534-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
195 Robotin MC, Kansil MQ, George J, Howard K, Tipper S, Levy M, Phung N, Penman AG. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res 2010;10:215. [PMID: 20663140 DOI: 10.1186/1472-6963-10-215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
196 Colombo M. Screening. Hepatology Research 2007;37:S146-51. [DOI: 10.1111/j.1872-034x.2007.00179.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Bolondi L, Piscaglia F, Gatta A, Salerno F, Bernardi M, Ascione A, Ferraù O, Sacerdoti D, Visentin S, Trevisani F, Mazzanti R, Donati G, Arena U, Gentilini P. Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. Clinical Gastroenterology and Hepatology 2006;4:1395-402. [DOI: 10.1016/j.cgh.2006.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
198 Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:272-82. [DOI: 10.1016/j.dld.2010.01.021] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 12.5] [Reference Citation Analysis]
199 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
200 Kong CQ, Chen XC, Qiu GH, Liang JC, Wang D, Liu XY, Liu JJ, Han YQ, Fan XH. Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line. Biomed Res Int 2021;2021:6638915. [PMID: 33628799 DOI: 10.1155/2021/6638915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
202 Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol. 2016;14:875-886.e6. [PMID: 26775025 DOI: 10.1016/j.cgh.2015.12.042] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 17.0] [Reference Citation Analysis]
203 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
204 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
205 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
206 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
207 Fujita K, Kinukawa H, Ohno K, Ito Y, Saegusa H, Yoshimura T. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II. Clin Biochem 2015;48:1330-6. [PMID: 26210849 DOI: 10.1016/j.clinbiochem.2015.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
208 Bolondi L, Correas JM, Lencioni R, Weskott HP, Piscaglia F. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig Liver Dis. 2007;39:187-195. [PMID: 17208526 DOI: 10.1016/j.dld.2006.08.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
209 Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873-881. [PMID: 15946134 DOI: 10.1111/j.1440-1746.2005.03844.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
210 Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol 2008;3 Suppl 2:S87-S100. [PMID: 18309007 DOI: 10.2215/CJN.03320807] [Cited by in Crossref: 77] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
211 Liu Q, Shi H, Yang J, Jiang N. Long Non-Coding RNA NEAT1 Promoted Hepatocellular Carcinoma Cell Proliferation and Reduced Apoptosis Through the Regulation of Let-7b-IGF-1R Axis. Onco Targets Ther 2019;12:10401-13. [PMID: 31819522 DOI: 10.2147/OTT.S217763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
212 Guarino M, Stroffolini T, Lombardo FL, Loperto I, Auriemma F, Gentile I, Caporaso N, Morisco F. Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. J Med Virol 2015;87:1368-76. [PMID: 25802203 DOI: 10.1002/jmv.24187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
213 Kiyokawa H, Yasuda H, Oikawa R, Okuse C, Matsumoto N, Ikeda H, Watanabe T, Yamamoto H, Itoh F, Otsubo T, Yoshimura T, Yoshida E, Nakagawa M, Koshikawa N, Seiki M. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma. Cancer Sci 2017;108:1432-9. [PMID: 28418226 DOI: 10.1111/cas.13261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
214 Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;8:2547-2557. [PMID: 19032223 DOI: 10.1111/j.1600-6143.2008.02409.x] [Cited by in Crossref: 236] [Cited by in F6Publishing: 219] [Article Influence: 18.2] [Reference Citation Analysis]
215 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 194] [Article Influence: 24.6] [Reference Citation Analysis]
216 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 161] [Article Influence: 26.6] [Reference Citation Analysis]
217 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580-585. [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
218 Sherman M. Screening for hepatocellular carcinoma. Hepatology Research 2007;37:S152-65. [DOI: 10.1111/j.1872-034x.2007.00180.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
219 Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol. 2012;57:663-674. [PMID: 22609306 DOI: 10.1016/j.jhep.2012.02.035] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 10.3] [Reference Citation Analysis]
220 Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009;137:26-29. [PMID: 19482098 DOI: 10.1053/j.gastro.2009.05.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
221 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Guía para el diagnóstico, estadificación y tratamiento del hepatocarcinoma. Medicina Clínica 2007;128:741-8. [DOI: 10.1157/13106134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
222 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
223 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
224 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
225 Chung JW, Jang ES, Kim J, Jeong SH, Kim N, Lee DH, Lee KH, Kim JW. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2017;8:106499-510. [PMID: 29290966 DOI: 10.18632/oncotarget.22498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
226 Meijer K, Haagsma EB. HCV-related liver cancer in people with haemophilia: HCV-RELATED LIVER CANCER IN HAEMOPHILIA. Haemophilia 2012;18:17-24. [DOI: 10.1111/j.1365-2516.2011.02575.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
227 Asham EH, Kaseb A, Ghobrial RM. Management of Hepatocellular Carcinoma. Surgical Clinics of North America 2013;93:1423-50. [DOI: 10.1016/j.suc.2013.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
228 Georgiades CS, Ramsey DE, Solomon S, Geschwind JH. New nonsurgical therapies in the treatment of hepatocellular carcinoma. Techniques in Vascular and Interventional Radiology 2001;4:193-9. [DOI: 10.1016/s1089-2516(01)90025-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
229 Min JH, Kim JM, Kim YK, Cha DI, Kang TW, Kim H, Choi GS, Choi S, Ahn S. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Clinical Gastroenterology and Hepatology 2020;18:2091-2100.e7. [DOI: 10.1016/j.cgh.2019.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
230 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
231 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
232 Carmi L, Georgiades C. Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: a review. Semin Intervent Radiol. 2010;27:296-301. [PMID: 22550369 DOI: 10.1055/s-0030-1261788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
233 Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat 2017;24:982-9. [PMID: 28414893 DOI: 10.1111/jvh.12717] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
234 Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, Wang K, Pan H. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193-200. [PMID: 24224779 DOI: 10.1111/jgh.12441] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
235 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
236 Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51. [PMID: 18039202 DOI: 10.1111/j.1872-034x.2007.00216.x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 82] [Article Influence: 19.2] [Reference Citation Analysis]
237 Sinn DH, Yi J, Choi MS, Choi D, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatol Int 2013;7:1010-8. [PMID: 26202030 DOI: 10.1007/s12072-013-9462-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
238 Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012;5:49-54. [PMID: 22826645 DOI: 10.2147/RMHP.S18677] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
239 Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004;127:S104-7. [PMID: 15508072 DOI: 10.1053/j.gastro.2004.09.022] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
240 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
241 Falagas ME, Vardakas KZ, Vergidis PI. Under-diagnosis of common chronic diseases: prevalence and impact on human health: Under-diagnosis of common diseases. International Journal of Clinical Practice 2007;61:1569-79. [DOI: 10.1111/j.1742-1241.2007.01423.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
242 Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434. [PMID: 20659234 DOI: 10.1111/j.1440-1746.2010.06285.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
243 Yang SW, Kim GH, Chung JW, Sohn HR, Lee SS, Hong S, Chung SM, Jang ES, Jeong SH, Kim JW. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy. J Gastroenterol Hepatol 2015;30:1175-82. [PMID: 25707935 DOI: 10.1111/jgh.12921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
244 Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 2007;37:S178-92. [DOI: 10.1111/j.1872-034x.2007.00183.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
245 Tanaka H, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, Ohnishi H, Miyoshi K, Iwado S, Iwasaki Y, Sakaguchi K, Shiratori Y. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006;26:543-51. [DOI: 10.1111/j.1478-3231.2006.01270.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
246 Wang LK, Xie XN, Song XH, Su T, Chang XL, Xu M, Liang B, Huang DY. Upregulation of miR-200b Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration by Targeting HMGB3 Protein. Technol Cancer Res Treat 2018;17:1533033818806475. [PMID: 30343649 DOI: 10.1177/1533033818806475] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
247 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
248 Worland T, Harrison B, Delmenico L, Dowling D. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. J Gastrointest Cancer 2018;49:476-80. [PMID: 28920172 DOI: 10.1007/s12029-017-0006-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
250 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
251 Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6. [PMID: 27438343 DOI: 10.1080/00365513.2016.1210328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
252 Del Poggio P, Olmi S, Ciccarese F, Mazzoleni M, Jazzetti M, Jamoletti C, Mattiello M, Del Poggio A, Portugali V, Stroffolini T. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2015;27:1103-8. [PMID: 26049705 DOI: 10.1097/MEG.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
253 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383-91.e6. [PMID: 25747273 DOI: 10.1053/j.gastro.2015.02.055] [Cited by in Crossref: 203] [Cited by in F6Publishing: 213] [Article Influence: 29.0] [Reference Citation Analysis]
254 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006;387:349-360. [PMID: 16606331 DOI: 10.1515/bc.2006.047] [Cited by in Crossref: 183] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
255 Park H, Kim SU, Kim D, Kim do Y, Ahn SH, Han KH, Chon CY, Park JY. Optimal time for restoring the reliability of liver stiffness measurement in patients with chronic hepatitis B experiencing acute exacerbation. J Clin Gastroenterol. 2012;46:602-607. [PMID: 22772739 DOI: 10.1097/mcg.0b013e3182582a31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
256 Staunton M, Dodd JD, McCormick PA, Malone DE. Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization? Radiology 2005;237:404-13. [PMID: 16244249 DOI: 10.1148/radiol.2372040058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
257 Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) 2016;95:e3328. [PMID: 27057911 DOI: 10.1097/MD.0000000000003328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
258 Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA. Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med 2016;32:110-5. [PMID: 27413728 DOI: 10.1159/000445407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
259 Wang DD, Qian XK, Li HX, Jia GH, Jin Q, Luan X, Zhu YD, Wang YN, Huang J, Zou LW, Ge GB, Yang L. Sensing and imaging of exosomal CD26 secreted from cancer cells and 3D colorectal tumor model using a novel near-infrared fluorogenic probe. Mater Sci Eng C Mater Biol Appl 2021;130:112472. [PMID: 34702509 DOI: 10.1016/j.msec.2021.112472] [Reference Citation Analysis]
260 Chang KC, Lu SN, Chen PF, Hung CH, Kee KM, Yen YH, Wang JH. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study. Kaohsiung J Med Sci 2011;27:85-90. [PMID: 21421195 DOI: 10.1016/j.kjms.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
261 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
262 Chen VL, Le AK, Kim NG, Kim LH, Nguyen NH, Nguyen PP, Zhao C, Nguyen MH. Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:887-895.e1. [PMID: 26820401 DOI: 10.1016/j.cgh.2015.12.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
263 Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
264 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
265 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
266 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
267 Naik AD, Arney J, Clark JA, Martin LA, Walling AM, Stevenson A, Smith D, Asch SM, Kanwal F. Integrated Model for Patient-Centered Advanced Liver Disease Care. Clinical Gastroenterology and Hepatology 2020;18:1015-24. [DOI: 10.1016/j.cgh.2019.07.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
268 Talwalkar JA, Kamath PS. Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis. Mayo Clinic Proceedings 2005;80:1501-8. [DOI: 10.4065/80.11.1501] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
269 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
270 Ravaioli M, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Cucchetti A, Pinna AD. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg. 2011;253:378-384. [PMID: 21183851 DOI: 10.1097/sla.0b013e318206818b] [Cited by in Crossref: 67] [Cited by in F6Publishing: 15] [Article Influence: 6.1] [Reference Citation Analysis]
271 Han S, Choi JI, Park MY, Choi MH, Rha SE, Lee YJ. The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol 2018;19:568-77. [PMID: 29962863 DOI: 10.3348/kjr.2018.19.4.568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
272 Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004;127:S126-S132. [PMID: 15508076 DOI: 10.1053/j.gastro.2004.09.026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
273 Thein HH, Khoo E, Campitelli MA, Zaheen A, Yi Q, De P, Earle CC. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open 2015;3:E208-16. [PMID: 26389099 DOI: 10.9778/cmajo.20140118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
274 Rapaccini GL, Pompili M, Caturelli E, Covino M, Lippi ME, Beccaria S, Cedrone A, Riccardi L, Siena DA, Gasbarrini G. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004;24:124-30. [DOI: 10.1111/j.1478-3231.2004.0903.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
275 Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis. J Ultrasound 2009;12:118-24. [PMID: 23396874 DOI: 10.1016/j.jus.2009.05.003] [Reference Citation Analysis]
276 Ritorto MS, Borlak J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. J Proteome Res 2011;10:3012-30. [PMID: 21644509 DOI: 10.1021/pr101207t] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
277 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
278 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
279 Kuftinec G, Loehfelm T, Corwin M, Durbin-Johnson B, Candido M, Hluhanich R, Sarkar S. De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents. Hepat Oncol 2018;5:HEP06. [PMID: 30302197 DOI: 10.2217/hep-2018-0003] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
280 Albrecht T. HCC-Screening. Radiologe 2008;48:33-8. [DOI: 10.1007/s00117-007-1590-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
281 De Giorgio M, Fagiuoli S. Management of hepatocellular carcinoma. Dig Dis 2007;25:279-81. [PMID: 17827957 DOI: 10.1159/000103902] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
282 Jain D. Diagnosis of hepatocellular carcinoma: fine needle aspiration cytology or needle core biopsy. J Clin Gastroenterol 2002;35:S101-8. [PMID: 12394213 DOI: 10.1097/00004836-200211002-00006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
283 Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF, Pinna AD. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880-888. [PMID: 20409605 DOI: 10.1016/j.jhep.2009.12.037] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 9.2] [Reference Citation Analysis]
284 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
285 Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One 2013;8:e68904. [PMID: 23874805 DOI: 10.1371/journal.pone.0068904] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
286 Trevisani F, Magini G, Santi V, Morselli-labate AM, Chiara Cantarini M, Anna Di Nolfo M, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; for the Italian Liver Cancer (ITA.LI.CA) Group. Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. CME. Am J Gastroenterology 2007;102:1022-31. [DOI: 10.1111/j.1572-0241.2007.01100.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
287 Nakano M, Ando E, Kuromatsu R, Torimura T, Sumie S, Takata A, Fukushima N, Kurogi J, Niizeki T, Iwamoto H, Tanaka M, Sata M. Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan: Recent progress in surveillance for liver cancer. Hepatology Research 2010;40:989-96. [DOI: 10.1111/j.1872-034x.2010.00706.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
288 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536-543. [PMID: 12677151 DOI: 10.1097/00000658-200304000-00016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
289 Bartolomeo N, Trerotoli P, Serio G. Progression of liver cirrhosis to HCC: an application of hidden Markov model. BMC Med Res Methodol 2011;11:38. [PMID: 21457586 DOI: 10.1186/1471-2288-11-38] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
290 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
291 Schaff Z, Kovalszky I, Lotz G, Kiss A. Hepatocellular carcinoma – from macroscopy to molecular pathology. Orvosi Hetilap 2010;151:982-9. [DOI: 10.1556/oh.2010.28875] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
292 El-serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 2008;134:1752-63. [DOI: 10.1053/j.gastro.2008.02.090] [Cited by in Crossref: 690] [Cited by in F6Publishing: 649] [Article Influence: 49.3] [Reference Citation Analysis]
293 Han KH, Kim DY, Park JY, Ahn SH, Kim J, Kim SU, Kim JK, Lee KS, Chon CY. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. J Clin Gastroenterol. 2013;47:538-544. [PMID: 23340065 DOI: 10.1097/mcg.0b013e3182755c13] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
294 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [78495111110.1046/j.1365-2036.17.s2.21.x','', '1948-5182')">Reference Citation Analysis]
295 Kim SA, Cho EJ, Lee S, Cho YY, Kim B, Yoon JH, Park T. Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. Sci Rep 2020;10:21313. [PMID: 33277619 DOI: 10.1038/s41598-020-78440-w] [Reference Citation Analysis]
296 Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011;6 Suppl 1:93-8. [PMID: 22009618 DOI: 10.1007/s11739-011-0682-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
297 Li R, Cai P, Ma KS, Ding SY, Guo DY, Yan XC. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci Rep. 2016;6:26772. [PMID: 27226026 DOI: 10.1038/srep26772] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
298 Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A, Fornari F, Del Vecchio Blanco C, de Sio I. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut. 2004;53:1356-1362. [PMID: 15306600 DOI: 10.1136/gut.2003.032359] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]
299 Sala M, Varela M, Forner A, Bruix J. [Early diagnosis of liver cancer]. Gastroenterol Hepatol 2005;28:292-7. [PMID: 15871814 DOI: 10.1157/13074066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
300 Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, Flores A, Ankoma-Sey V, Luxon B, Volk M. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69:1787-1797. [PMID: 30586188 DOI: 10.1002/hep.30489] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
301 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
302 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Kim SS, Cho HJ, Lee HY, Park JH, Noh CK, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma. Clin Biochem. 2016;49:792-801. [PMID: 26968103 DOI: 10.1016/j.clinbiochem.2016.01.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
304 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
305 Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826-835. [PMID: 19960258 DOI: 10.1007/s10620-009-1059-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
306 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
307 Lau WY. Future perspectives for hepatocellular carcinoma. HPB (Oxford) 2003;5:206-13. [PMID: 18332989 DOI: 10.1080/13651820310016779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
308 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
309 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
310 Chan ACY, Poon RTP, Ng KKC, Lo CM, Fan ST, Wong J. Changing Paradigm in the Management of Hepatocellular Carcinoma Improves the Survival Benefit of Early Detection by Screening. Annals of Surgery 2008;247:666-73. [DOI: 10.1097/sla.0b013e31816a747a] [Cited by in Crossref: 68] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
311 Chang A, Abbott DE. Cost-Effectiveness Analysis in Cancer Care. Cancer Treat Res 2016;168:377-91. [PMID: 29206384 DOI: 10.1007/978-3-319-34244-3_18] [Reference Citation Analysis]
312 Omran D, Esmat S, Sedrac H, Elbadry A, Ismail D, Rashed L. Can we use GP73 as a biomarker for the detection of hepatocellular carcinoma?: . Egyptian Liver Journal 2011;1:43-6. [DOI: 10.1097/01.elx.0000397027.33294.16] [Reference Citation Analysis]
313 Zhou Q, Li Z, Zhou J, Joshi BP, Li G, Duan X, Kuick R, Owens SR, Wang TD. In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. Photoacoustics 2016;4:43-54. [PMID: 27766208 DOI: 10.1016/j.pacs.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
314 Ben Chaabane N, Jeridi N, Loghmari H, Melki W, Hellara O, Bdioui F, Safer L, Saffar H. Programme de surveillance des patients cirrhotiques pour le diagnostic précoce et le traitement du carcinome hépatocellulaire en Tunisie : analyse coût-efficacité. J Afr Hepato Gastroenterol 2011;5:159-62. [DOI: 10.1007/s12157-011-0268-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
315 Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012;56:397-405. [DOI: 10.1016/j.jhep.2011.05.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
316 Arguedas MR. Screening for hepatocellular carcinoma: Why, when, how? Curr Gastroenterol Rep 2003;5:57-62. [DOI: 10.1007/s11894-003-0010-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
317 Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:101-118. [PMID: 15757807 DOI: 10.1016/j.bpg.2004.11.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
318 Trapé J, Botargues JM, Porta F, Ricós C, Badal JM, Salinas R, Sala M, Roca A. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;49:1209-11. [PMID: 12816928 DOI: 10.1373/49.7.1209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
319 Liu Z, Chang Q, Yang F, Liu B, Yao HW, Bai ZG, Pu CS, Ma XM, Yang Y, Wang TT, Guo W, Zhou XN, Zhang ZT. Long non-coding RNA NEAT1 overexpression is associated with unfavorable prognosis in patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study. Eur J Surg Oncol 2017;43:1697-703. [PMID: 28732670 DOI: 10.1016/j.ejso.2017.06.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
320 Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672-681. [PMID: 12827551 DOI: 10.1053/jlts.2003.50120] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 2.8] [Reference Citation Analysis]
321 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
322 Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26-34. [PMID: 18333158 DOI: 10.1080/13651820410024049] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 11.0] [Reference Citation Analysis]
323 Zhang W, Wang X, Jiang R, Hou J, Mu X, Li G, Sun B. Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. Mayo Clin Proc 2015;90:1187-95. [PMID: 26231292 DOI: 10.1016/j.mayocp.2015.06.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
324 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
325 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
326 Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734-744. [PMID: 11922571 DOI: 10.1111/j.1572-0241.2002.05557.x] [Cited by in Crossref: 212] [Cited by in F6Publishing: 202] [Article Influence: 10.6] [Reference Citation Analysis]
327 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
328 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 481] [Article Influence: 56.1] [Reference Citation Analysis]
329 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
330 Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:432. [PMID: 25502085 DOI: 10.1007/s12032-014-0432-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
331 Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol 2006;20:257-60. [PMID: 16609753 DOI: 10.1155/2006/428048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
332 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
333 Yasuda H, Nakagawa M, Kiyokawa H, Yoshida E, Yoshimura T, Koshikawa N, Itoh F, Seiki M. Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review. Int J Mol Sci 2019;20:E226. [PMID: 30626121 DOI: 10.3390/ijms20010226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
334 Piscaglia F, Lencioni R, Sagrini E, Pina CD, Cioni D, Vidili G, Bolondi L. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol. 2010;36:531-550. [PMID: 20350680 DOI: 10.1016/j.ultrasmedbio.2010.01.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
335 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
336 Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol. 2003;14:1463-1467. [PMID: 14504044 DOI: 10.1093/annonc/mdg400] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
337 Velázquez R. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7. [DOI: 10.1053/jhep.2003.50093] [Cited by in Crossref: 286] [Cited by in F6Publishing: 263] [Article Influence: 15.1] [Reference Citation Analysis]
338 Arnold E, Yuan Y, Iloeje U, Cook G. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008;6:231-46. [DOI: 10.1007/bf03256136] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
339 Lee YH, Choi KS, Jun JK, Suh M, Lee HY, Kim YN, Nam CM, Park EC, Cho WH. Cost-effectiveness of liver cancer screening in adults at high risk for liver cancer in the republic of Korea. Cancer Res Treat 2014;46:223-33. [PMID: 25038757 DOI: 10.4143/crt.2014.46.3.223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
340 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States: NAFLD May Be a Common Underlying Liver Disease in Patients With Hepatocellular Carcinoma in the United States. Hepatology 2002;36:1349-54. [DOI: 10.1002/hep.1840360609] [Cited by in Crossref: 255] [Cited by in F6Publishing: 123] [Article Influence: 17.0] [Reference Citation Analysis]
341 Watts AC, Teoh K, Evans T, Beggs I, Robb J, Porter D. MRI surveillance after resection for primary musculoskeletal sarcoma. The Journal of Bone and Joint Surgery British volume 2008;90-B:484-7. [DOI: 10.1302/0301-620x.90b4.20089] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
342 Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. Hepatol Int 2008;2:231-6. [PMID: 19669309 DOI: 10.1007/s12072-008-9054-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
343 Georgiades CS, Hong K, Geschwind J. Pre- and Postoperative Clinical Care of Patients Undergoing Interventional Oncology Procedures: A Comprehensive Approach to Preventing and Mitigating Complications. Techniques in Vascular and Interventional Radiology 2006;9:113-24. [DOI: 10.1053/j.tvir.2007.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
344 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
345 Colombo M. Natural history of hepatocellular carcinoma. Cancer Imaging 2005;5:85-8. [PMID: 16154825 DOI: 10.1102/1470-7330.2005.0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
346 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
347 Yan J, Yang X, Li L, Liu P, Wu H, Liu Z, Li Q, Liao G, Wang X. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma. Oncol Lett 2017;13:3395-402. [PMID: 28521445 DOI: 10.3892/ol.2017.5934] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
348 Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernández-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer. 2007;7:28. [PMID: 17288606 DOI: 10.1186/1471-2407-7-28] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
349 Wei Y, Gong J, He X, Liu B, Liu T, Yang S, Zhou Z, Liang L, Zhan S, Xia Z, Duan G, Lin B, Han Q, Li S, Qin W, Pickhardt PJ, Deng D. An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis. Front Oncol 2022;12:800787. [DOI: 10.3389/fonc.2022.800787] [Reference Citation Analysis]
350 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013; 19(9): 1359-1371 [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
351 Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T, Arihiro K, Okajima M, Asahara T. Rho-Associated Kinase Inhibitor Reduces Tumor Recurrence After Liver Transplantation in a Rat Hepatoma Model. Am J Transplant 2007;7:347-55. [DOI: 10.1111/j.1600-6143.2006.01647.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
352 Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, Goto T, Kanai F, Obi S, Kato N, Shiina S, Kawabe T, Omata M. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544-550. [PMID: 19669240 DOI: 10.1007/s12072-009-9145-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
353 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
354 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
355 Jiang L, Cheng Q, Zhang BH, Zhang MZ. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China. Medicine (Baltimore). 2015;94:e603. [PMID: 25761179 DOI: 10.1097/md.0000000000000603] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
356 Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Sezaki H. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol. 2006;44:1089-1097. [PMID: 16618514 DOI: 10.1016/j.jhep.2006.02.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
357 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
358 Lui HF. Screening for hepatocellular carcinoma. Int J Hepatol 2011;2011:363151. [PMID: 22028976 DOI: 10.4061/2011/363151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
359 Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim H. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int 2017;37:879-87. [DOI: 10.1111/liv.13341] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
360 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
361 Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology. 2013;266:480-490. [PMID: 23362095 DOI: 10.1148/radiol.12112677] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 10.1] [Reference Citation Analysis]
362 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
363 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
364 Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis: EVALUATING ANTI-VIRAL THERAPY IN HBEAG-NEGATIVE CHB. Alimentary Pharmacology & Therapeutics 2008;27:1240-52. [DOI: 10.1111/j.1365-2036.2008.03691.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
365 Maciel AC, Cerski CT, Moreira RK, Resende VL, Zanotelli ML, Matiotti SB. Hepatocellular carcinoma in patients undergoing orthotopic liver transplantation: radiological findings with anatomopathological correlation in Brazil. Arq Gastroenterol 2006;43:24-9. [DOI: 10.1590/s0004-28032006000100008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
366 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
367 Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013;2:227-231. [PMID: 24570947 DOI: 10.3978/j.issn.2304-3881.2013.08.11] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
368 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. Journal of Hepatology 2003;39:1076-84. [DOI: 10.1016/s0168-8278(03)00349-0] [Cited by in Crossref: 135] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
369 Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563-1570. [PMID: 25042054 DOI: 10.1002/hep.27305] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 19.1] [Reference Citation Analysis]
370 Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B: . PharmacoEconomics 2007;25:963-77. [DOI: 10.2165/00019053-200725110-00006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
371 Schölmerich J, Schacherer D. Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 2004;53:1224-6. [PMID: 15306574 DOI: 10.1136/gut.2004.040816] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
372 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
373 Couvert P, Carrié A, Pariès J, Vaysse J, Miroglio A, Kerjean A, Nahon P, Chelly J, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol 2008; 14(35): 5419-5427 [PMID: 18803353 DOI: 10.3748/wjg.14.5419] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
374 Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J 2013;43:197-203. [PMID: 22372378 DOI: 10.1111/j.1445-5994.2012.02755.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
375 Li QM, Zhang FQ, Li YF, Xian QJ, Zhang YQ, Li P. Influence of polymorphisms in the Wnt/β-catenin pathway genes on hepatocellular carcinoma risk in a Chinese Han population. Medicine (Baltimore) 2017;96:e6127. [PMID: 28328801 DOI: 10.1097/MD.0000000000006127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
376 Schima W, Kölblinger C, Ba-Ssalamah A. Non-invasive diagnosis of focal liver lesions: an individualized approach. Cancer Imaging 2012;12:365-72. [PMID: 23023267 DOI: 10.1102/1470-7330.2012.9025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
377 Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 2011;41:447-454. [PMID: 21411469 DOI: 10.1093/jjco/hyr016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
378 Andreana L, Isgrò G, Pleguezuelo M, Germani G, Burroughs AK. Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol 2009; 1(1): 48-61 [PMID: 21160965 DOI: 10.4254/wjh.v1.i1.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
379 Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519. [PMID: 20397916 DOI: 10.1586/era.10.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
380 Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J 2007;37:516-22. [PMID: 17543001 DOI: 10.1111/j.1445-5994.2007.01392.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
381 Wang S, Wang JQ, Lv XW. Exosomal miRNAs as biomarkers in the diagnosis of liver disease. Biomark Med 2017;11:491-501. [PMID: 28598214 DOI: 10.2217/bmm-2017-0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
382 . Chapter 2: Diagnosis and surveillance: Chapter 2: Diagnosis and surveillance. Hepatology Research 2010;40:16-47. [DOI: 10.1111/j.1872-034x.2010.00655.x] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
383 Wu C, Lin J. The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. Best Practice & Research Clinical Gastroenterology 2015;29:843-53. [DOI: 10.1016/j.bpg.2015.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
384 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
385 Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11:95-101. [PMID: 22982095 DOI: 10.1016/j.cgh.2012.09.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
386 Kobayashi T, Aikata H, Kobayashi T, Ohdan H, Arihiro K, Chayama K. Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary & Pancreatic Diseases International 2017;16:279-88. [DOI: 10.1016/s1499-3872(16)60181-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
387 Tiwari AK, Laird-Fick HS, Wali RK, Roy HK. Surveillance for gastrointestinal malignancies. World J Gastroenterol 2012; 18(33): 4507-4516 [PMID: 22969223 DOI: 10.3748/wjg.v18.i33.4507] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
388 Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH. A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements. Clin Transl Gastroenterol 2018;9:183. [PMID: 30237482 DOI: 10.1038/s41424-018-0050-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
389 Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res 2018;48:1118-30. [PMID: 30030881 DOI: 10.1111/hepr.13232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
390 Herber SC, Otto G, Schneider J, Schuchmann M, Düber C, Pitton MB, Kummer I, Manzl N. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol. 2008;190:1035-1042. [PMID: 18356452 DOI: 10.2214/ajr.07.2755] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
391 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536-543. [PMID: 12677151 DOI: 10.1097/01.sla.0000059988.22416.f2] [Cited by in Crossref: 159] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
392 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
393 Jia KD, Shi SX, Ruan YB. Relationship between expression of survivin gene and proliferation of hepatocytes in liver cirrhosis and hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2004; 12(3): 550-554 [DOI: 10.11569/wcjd.v12.i3.550] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
394 Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:259-264. [PMID: 17174610 DOI: 10.1016/j.cgh.2006.09.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
395 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
396 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 9.9] [Reference Citation Analysis]
397 Nissen NN, Martin P. Hepatocellular Carcinoma: The High-Risk Patient. Journal of Clinical Gastroenterology 2002;35:S79-85. [DOI: 10.1097/00004836-200211002-00003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
398 Danta M, Barnes E, Dusheiko G. The surveillance and diagnosis of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:491-6. [DOI: 10.1097/00042737-200505000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
399 Kallwitz ER, Cotler SJ. Screening for Hepatocellular Carcinoma in Clinical Practice: Miles to Go Before We Sleep. Journal of Clinical Gastroenterology 2007;41:729-30. [DOI: 10.1097/mcg.0b013e3180544951] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
400 Yang H, Chen G, Fang F, Liu Z, Hiu Yan Lau S, Zhang J, Lau WY, Yang L. Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. Int J Biol Markers 2013;28:286-97. [DOI: 10.5301/jbm.5000015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
401 Fujimoto K, Sawabe M, Sasaki M, Kino K, Arai T. Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments. Geriatr Gerontol Int. 2008;8:198-203. [PMID: 18822004 DOI: 10.1111/j.1447-0594.2008.00470.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
402 Xu Q, Liu X, Zheng X, Yao Y, Liu Q. PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol Lett 2014;8:1973-9. [PMID: 25289083 DOI: 10.3892/ol.2014.2441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
403 Tanaka H, Iijima H, Nouso K, Aoki N, Iwai T, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Nishiguchi S. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography: Cost-effectiveness of CEUS surveillance for HCC. Hepatology Research 2012;42:376-84. [DOI: 10.1111/j.1872-034x.2011.00936.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
404 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
405 Ohto M, Ito R, Soma N, Fukuda H, Shinohara Y, Sakamoto A, Kondo F. Contrast-enhanced 3D ultrasonography in minute hepatocellular carcinoma. J Med Ultrason (2001) 2011;38:3-12. [PMID: 27278332 DOI: 10.1007/s10396-010-0283-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
406 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
407 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
408 Chang Y, Lairson DR, Chan W, Lu S, Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk: Cost-effectiveness of screening for HCC. Journal of Evaluation in Clinical Practice 2011;17:261-7. [DOI: 10.1111/j.1365-2753.2010.01432.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
409 Heiat M, Negahdary M. Sensitive diagnosis of alpha-fetoprotein by a label free nanoaptasensor designed by modified Au electrode with spindle-shaped gold nanostructure. Microchemical Journal 2019;148:456-66. [DOI: 10.1016/j.microc.2019.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
410 Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, D'errico A, Ballardini G, Cavallari A, Grazi GL. Liver transplantation for hepatocellular carcinoma: Further considerations on selection criteria. Liver Transpl 2004;10:1195-202. [DOI: 10.1002/lt.20239] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
411 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
412 Gennari R, Veronesi U, Andreoli C, Betka J, Castelli A, Gatti G, Hugosson J, Llovet JM, Melia J, Nakhosteen JA, Pastorino U, Sideri M, Stephan C, Veronesi P, Zurrida S. Early detection of cancer: ideas for a debate. Crit Rev Oncol Hematol 2007;61:97-103. [PMID: 17113782 DOI: 10.1016/j.critrevonc.2006.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
413 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
414 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 10.9] [Reference Citation Analysis]
415 Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2009;16:413-422. [PMID: 19034578 DOI: 10.1245/s10434-008-0232-4] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
416 Peyton A, Martin P. Primary Care of Patients with Cirrhosis – Current and Future Challenges. Curr Hepatology Rep 2014;13:1-7. [DOI: 10.1007/s11901-014-0219-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
417 Caumes JL, Nousbaum JB, Bessaguet C, Fayçal J, Robaszkiewicz M, Gouérou H. Epidemiology of hepatocellular carcinoma in Finistère. Prospective study from June 2002 to May 2003. Gastroenterol Clin Biol 2007;31:259-64. [PMID: 17396082 DOI: 10.1016/s0399-8320(07)89370-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
418 Manzione L, Grimaldi AM, Romano R, Ferrara D, Dinota A. Hepatocarcinoma: from pathogenic mechanisms to target therapy. Oncol Rev 2008;2:214-22. [DOI: 10.1007/s12156-008-0077-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
419 Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76. [PMID: 19925500 DOI: 10.1111/j.1365-2036.2009.04200.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 9.9] [Reference Citation Analysis]
420 Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K. The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. J Clin Gastroenterol. 2015;Epub ahead of print. [PMID: 25751372 DOI: 10.1097/mcg.0000000000000306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
421 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 47] [Article Influence: 11.7] [Reference Citation Analysis]
422 Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program. Value in Health 2008;11:S11-22. [DOI: 10.1111/j.1524-4733.2008.00362.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
423 Kuetting F, Lang S, Schramm C, Kasper P, Goeser T, Steffen H, Demir M. FIB-4 Is a Potential Tool for Hepatocellular Carcinoma Risk Stratification in Ethnically Diverse Chronic Hepatitis B Patients When Using Specific Cutoff Values. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.94574] [Reference Citation Analysis]
424 Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011;141:141-9. [PMID: 21440548 DOI: 10.1053/j.gastro.2011.03.045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 9.1] [Reference Citation Analysis]